CUV 1.85% $13.28 clinuvel pharmaceuticals limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 776 Posts.
    lightbulb Created with Sketch. 223
    Agree with most comments. I was hoping for 16-17 (anything above a bonus) - hence on the surface it looks pretty ordinary. The reasons are not clear but could be last comparison 1/4 was boosted by lag payments, current 1/4 could have outstanding payments, the seasonal weather this year, a lack of demand in the cold months (could be an ongoing situation but offset by higher warmer months uptake). Just in case CUV need to widen the demand by 10-18 yo, Australia and Asia and UK. As far as recent price strength, I’m perplexed and don’t get why volumes weren’t higher and shorts reducing. I don’t imagine larger investors coming on board just did it on the basis of one quarterly but it could drop back from here also?? I’m also concerned about the whole market and more interest rate rises. Plenty of money in the bank and no debt so it still a good hold under $30 IMO. Also Mitsubishi Tanabe might still be a way off in terms of competition. GLTA
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$13.28
Change
-0.250(1.85%)
Mkt cap ! $664.8M
Open High Low Value Volume
$13.55 $13.62 $13.25 $1.157M 86.45K

Buyers (Bids)

No. Vol. Price($)
1 227 $13.28
 

Sellers (Offers)

Price($) Vol. No.
$13.42 228 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.